Under the terms of the merger, approved by the boards of both companies, Endo will acquire Indevus for $370 million, or $4.50per share, in cash, plus up to an extra $267 million, or $3 per share, in cash "payable in the future upon achievement of certain milestones," according to a statement from Indevus.
"We believe Endo's proven commercial capabilities, targeted approach to medical marketing and unique understanding of the changes taking place in health care delivery today will ensure the success of our current and future products," said Dr. Glenn L. Cooper, chairman and chief executive officer of Indevus.
Endo shares closed down $2.03, or 7.8%, at $24.05 Monday, and Indevus shares closed down 5 cents, or 1.6%, at $3.10.An analyst at Caris & Co cut its rating on Endo to above average from buy Monday morning, saying the company's proposed near-term growth strategy was unclear.
Endo competes in the biotech space with Abbott Labs (ABT - Get Report) and Pfizer (PFE - Get Report). Indevus competes with Allergan (AGN), Johnson & Johnson (JNJ - Get Report) and Watson Pharmaceuticals (WPI).